[FG] Rentsch Cyrill

Papagiannakis, Alkiviadis et al. (2025) ‘Influence of Regular Statin Intake on Prostate‐Specific Antigen Values, Prostate Cancer Incidence and Overall Survival in a Prospective Screening Trial ( ERSPC Aarau)’, Cancer Medicine, 14(1). Available at: https://doi.org/10.1002/cam4.70485.

Sigg, S. et al. (2024) ‘Outcomes of robot-assisted laparoscopic extended pelvic lymph node dissection for prostate Cancer’, BMC Urology, 24(1). Available at: https://doi.org/10.1186/s12894-024-01409-8.

Engesser, Christian et al. (2024) ‘3D ‐printed model for resection of positive surgical margins in robot‐assisted prostatectomy’, BJU International [Preprint]. Available at: https://doi.org/10.1111/bju.16595.

Engesser, C. et al. (2024) ‘Clinical decision making in prostate cancer care—evaluation of EAU-guidelines use and novel decision support software’, Scientific Reports, 14(1). Available at: https://doi.org/10.1038/s41598-024-70292-y.

Kaufmann, B. et al. (2024) ‘Focal therapy with high-intensity focused ultrasound for prostate cancer: 3-year outcomes from a prospective trial’, BJU International, 133(4), pp. 413–424. Available at: https://doi.org/10.1111/bju.16213.

Alargkof, Viktor et al. (2024) ‘The learning curve for robotic-assisted transperineal MRI/US fusion-guided prostate biopsy’, Scientific Reports, 14(1). Available at: https://doi.org/10.1038/s41598-024-55492-w.

De Laere, B. et al. (2024) ‘Androgen receptor pathway inhibitors and taxanes in metastatic prostate cancer: an outcome-adaptive randomized platform trial’, Nature Medicine [Preprint]. Available at: https://doi.org/10.1038/s41591-024-03204-2.

Vlajnic, Tatjana et al. (2024) ‘Loss of MTAP Expression by Immunohistochemistry Is a Surrogate Marker for Homozygous 9p21.3 Deletion in Urothelial Carcinoma’, Modern Pathology, 37. Available at: https://doi.org/10.1016/j.modpat.2024.100495.

Wetterauer, Christian et al. (2024) ‘Opportunistic Prostate Cancer Screening with Biparametric Magnetic Resonance Imaging (VISIONING)’, European Urology Focus. 16.07.2024, 10(2), pp. 332–338. Available at: https://doi.org/10.1016/j.euf.2024.02.006.

Würnschimmel, Christoph et al. (2024) ‘Prostate cancer screening in Switzerland: a literature review and consensus statement from the Swiss Society of Urology’, Swiss Medical Weekly, 154. Available at: https://doi.org/10.57187/s.3626.

Lehner, F. et al. (2023) ‘Transperineal template saturation and conventional biopsy for stage prediction in prostate cancer’, BJU International, 132(6), pp. 696–704. Available at: https://doi.org/10.1111/bju.16181.

Wetterauer, C. et al. (2023) Opportunistic PSA-free prostate cancer screening utilising biparametric MRI (VISIONING). Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2023.09.07.23295039.

Lampart, F.L. et al. (2023) Morphometry and mechanical instability at the onset of epithelial bladder cancer. Cold Spring Harbor Laboratory. Available at: https://doi.org/10.1101/2023.08.17.553533.

Petrausch U et al. (2023) ‘Novel sequential treatment strategy for patients with muscle-invasive bladder cancer (MIBC): intravesical recombinant BCG, followed by neoadjuvant chemoimmunotherapy, radical cystectomy plus pelvic lymphadenectomy and adjuvant immunotherapy - protocol of a multicentre, single arm phase 2 trial (SAKK 06/19).’, BMJ open, 13(6), p. e067634. Available at: https://doi.org/10.1136/bmjopen-2022-067634.

MacLennan, S. et al. (2023) ‘Mapping European Association of Urology Guideline Practice Across Europe: An Audit of Androgen Deprivation Therapy Use Before Prostate Cancer Surgery in 6598 Cases in 187 Hospitals Across 31 European Countries’, European Urology, 83(5), pp. 393–401. Available at: https://doi.org/10.1016/j.eururo.2022.12.031.

Elyan, Anas et al. (2023) ‘Prospective Multicenter Validation of the Stockholm3 Test in a Central European Cohort’, European Urology Focus, null. Available at: https://doi.org/10.1016/j.euf.2023.09.016.

Ruiz, Christian et al. (2023) ‘Critical Evaluation of Transcripts and Long Noncoding RNA Expression Levels in Prostate Cancer Following Radical Prostatectomy’, Pathobiology, 90, pp. 400–408. Available at: https://doi.org/10.1159/000531175.

Scherer, T.P. et al. (2023) ‘Do Swiss urologists and Swiss internists screen themselves and their relatives for prostate cancer? A questionnaire study’, Swiss Medical Weekly, 153(9). Available at: https://doi.org/10.57187/smw.2023.40115.

Schmid FA et al. (2023) ‘Therapy decisions after diagnosis of prostate cancer in men with negative prostate MRI.’, The Prostate, 83(1), pp. 56–63. Available at: https://doi.org/10.1002/pros.24435.

Bacon JVW et al. (2022) ‘Somatic Features of Response and Relapse in Non-muscle-invasive Bladder Cancer Treated with Bacillus Calmette-Guérin Immunotherapy.’, European urology oncology, 5(6), pp. 677–686. Available at: https://doi.org/10.1016/j.euo.2021.11.002.

De Laere B et al. (2022) ‘Clinical Trial Protocol for ProBio: An Outcome-adaptive and Randomised Multiarm Biomarker-driven Study in Patients with Metastatic Prostate Cancer.’, European urology focus, 8(6), pp. 1617–1621. Available at: https://doi.org/10.1016/j.euf.2022.03.005.

Ferraro DA et al. (2022) ‘(68)Ga-PSMA-11 PET/MRI versus multiparametric MRI in men referred for prostate biopsy: primary tumour localization and interreader agreement.’, European journal of hybrid imaging, 6(1), p. 14. Available at: https://doi.org/10.1186/s41824-022-00135-4.

Chandra Engel J et al. (2022) ‘External Validation of the Prostate Biopsy Collaborative Group Risk Calculator and the Rotterdam Prostate Cancer Risk Calculator in a Swedish Population-based Screening Cohort.’, European urology open science, 41, pp. 1–7. Available at: https://doi.org/10.1016/j.euros.2022.04.010.

Rentsch CA, Hayoz S and Cathomas RL (2022) ‘Re: Pembrolizumab Monotherapy for the Treatment of High-risk Non-muscle-invasive Bladder Cancer Unresponsive to BCG (KEYNOTE-057): An Open-label, Single-arm, Multicenter, Phase 2 Study.’, European urology, 81(5), p. 542. Available at: https://doi.org/10.1016/j.eururo.2022.01.021.

Mortezavi A et al. (2022) ‘Association of Open vs Robot-Assisted Radical Cystectomy With Mortality and Perioperative Outcomes Among Patients With Bladder Cancer in Sweden.’, JAMA network open, 5(4), p. e228959. Available at: https://doi.org/10.1001/jamanetworkopen.2022.8959.

Rentsch CA et al. (2022) ‘A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.’, European urology oncology, 5(2), pp. 195–202. Available at: https://doi.org/10.1016/j.euo.2021.12.006.

Vlajnic T et al. (2022) ‘High Inter- and Intratumoral Variability of Ki67 Labeling Index in Newly Diagnosed Prostate Cancer with High Gleason Scores’, Pathobiology, 89(2), pp. 74–80. Available at: https://doi.org/10.1159/000519007.

Hosseini, A. and Mortezavi, A. (2022) ‘Robotic-Assisted Radical Cystectomy Outcomes’. Springer International Publishing, pp. 723–734. Available at: https://doi.org/10.1007/978-3-031-00363-9_65.

Wetterauer C et al. (2022) ‘Indication for Active Surveillance in the Era of MRI-Targeted Prostate Biopsies’, Urologia Internationalis, 106(1), pp. 83–89. Available at: https://doi.org/10.1159/000517300.

Bausch K et al. (2021) ‘Enhancing disease awareness for tuberous sclerosis complex in patients with radiologic diagnosis of renal angiomyolipoma: an observational study’, BMC Nephrology, 22(1), p. 47. Available at: https://doi.org/10.1186/s12882-021-02253-w.

Spitznagel T et al. (2021) ‘Salvage Robotic-assisted Laparoscopic Radical Prostatectomy Following Focal High-Intensity Focused Ultrasound for ISUP 2/3 Cancer.’, Urology, 156, pp. 147–153. Available at: https://doi.org/10.1016/j.urology.2021.04.059.

Ferraro DA et al. (2021) ‘Diagnostic performance of (68)Ga-PSMA-11 PET/MRI-guided biopsy in patients with suspected prostate cancer: a prospective single-center study.’, European journal of nuclear medicine and molecular imaging, 48(10), pp. 3315–3324. Available at: https://doi.org/10.1007/s00259-021-05261-y.

Rentsch C.A., Hayoz S. and Cathomas R. (2021) ‘Pembrolizumab monotherapy for high-risk, non-muscle-invasive bladder cancer’, The Lancet Oncology, 22(9), p. e379. Available at: https://doi.org/10.1016/s1470-2045(21)00390-9.

Servant R et al. (2021) ‘Prostate cancer patient-derived organoids: detailed outcome from a prospective cohort of 81 clinical specimens.’, The Journal of pathology, 254(5), pp. 543–555. Available at: https://doi.org/10.1002/path.5698.

Mortezavi A et al. (2021) ‘Morbidity and mortality after robot-assisted radical cystectomy with intracorporeal urinary diversion in octogenarians: results from the European Association of Urology Robotic Urology Section Scientific Working Group.’, BJU international, 127(5), pp. 585–595. Available at: https://doi.org/10.1111/bju.15274.

Mortezavi A et al. (2021) ‘Head-to-head Comparison of Conventional, and Image- and Biomarker-based Prostate Cancer Risk Calculators.’, European urology focus, 7(3), pp. 546–553. Available at: https://doi.org/10.1016/j.euf.2020.05.002.

Lantz A et al. (2021) ‘Effect of information on prostate biopsy history on biopsy outcomes in the era of MRI-targeted biopsies.’, World journal of urology, 39(4), pp. 1153–1159. Available at: https://doi.org/10.1007/s00345-020-03277-x.

De Laere B et al. (2021) ‘Increased Pathway Complexity Is a Prognostic Biomarker in Metastatic Castration-Resistant Prostate Cancer.’, Cancers, 13(7). Available at: https://doi.org/10.3390/cancers13071588.

Krause, Arthur et al. (2021) ‘Genomic evolutionary trajectory of metastatic squamous cell carcinoma of the lung’, Translational Lung Cancer Research, 10, pp. 1792–1803. Available at: https://doi.org/10.21037/tlcr-21-48.

Winkel DJ et al. (2020) ‘Autonomous detection and classification of pi-rads lesions in an mri screening population incorporating multicenter-labeled deep learning and biparametric imaging: Proof of concept’, Diagnostics, 10(11). Available at: https://doi.org/10.3390/diagnostics10110951.

Hosseini A et al. (2020) ‘Robot-assisted intracorporeal orthotopic bladder substitution after radical cystectomy: perioperative morbidity and oncological outcomes - a single-institution experience.’, BJU international, 126(4), pp. 464–471. Available at: https://doi.org/10.1111/bju.15112.

Federer-Gsponer JR et al. (2020) ‘Patterns of stemness-associated markers in the development of castration-resistant prostate cancer.’, The Prostate, 80(13), pp. 1108–1117. Available at: https://doi.org/10.1002/pros.24039.

Eberli D et al. (2020) ‘Apalutamide in combination with autophagy inhibitors improves treatment effects in prostate cancer cells.’, Urologic oncology, 38(8), p. 683.e19–683.e26. Available at: https://doi.org/10.1016/j.urolonc.2020.04.030.

Andreozzi M et al. (2020) ‘Corrigendum to “HMGA1 expression in human hepatocellular carcinoma correlates with poor prognosis and promotes tumor growth and migration in in vitro models” [Neoplasia 18 (2016) 724–731] (Neoplasia (2016) 18(12) (724–731), (S1476558616301634), (10.1016/j.neo.2016.10.002))’, 22(7). Available at: https://doi.org/10.1016/j.neo.2020.04.004.

Mortezavi A et al. (2020) ‘Association between PSA density and prostate cancer in men without significant MRI lesions.’, 125(6). Available at: https://doi.org/10.1111/bju.15037.

Dell-Kuster S et al. (2020) ‘The Importance of Standardised Recording of Intraoperative Adverse Events: Key Features of an Ideal Classification System’, 77(5). Available at: https://doi.org/10.1016/j.eururo.2020.01.024.

Saba K et al. (2020) ‘External Validation and Comparison of Prostate Cancer Risk Calculators Incorporating Multiparametric Magnetic Resonance Imaging for Prediction of Clinically Significant Prostate Cancer.’, The Journal of urology, 203(4), pp. 719–726. Available at: https://doi.org/10.1097/ju.0000000000000622.

Schmid FA et al. (2020) ‘Prospective multicentre study using high intensity focused ultrasound (HIFU) for the focal treatment of prostate cancer: Safety outcomes and complications.’, Urologic oncology, 38(4), pp. 225–230. Available at: https://doi.org/10.1016/j.urolonc.2019.09.001.

Martini A et al. (2020) ‘The natural history of untreated muscle-invasive bladder cancer.’, BJU international, 125(2), pp. 270–275. Available at: https://doi.org/10.1111/bju.14872.

Hendaoui I et al. (2020) ‘Tenascin-W Is a Novel Stromal Marker in Biliary Tract Cancers.’, Frontiers in immunology, 11, p. 630139. Available at: https://doi.org/10.3389/fimmu.2020.630139.

Rentsch CA et al. (2020) ‘Results of the phase I open label clinical trial SAKK 06/14 assessing safety of intravesical instillation of VPM1002BC, a recombinant mycobacterium Bacillus Calmette Guérin (BCG), in patients with non-muscle invasive bladder cancer and previous failure of conventional BCG therapy’, OncoImmunology, 9(1), p. 1748981. Available at: https://doi.org/10.1080/2162402X.2020.1748981.

Mortezavi A et al. (2019) ‘Extensive Histological Sampling following Focal Therapy of Clinically Significant Prostate Cancer with High Intensity Focused Ultrasound.’, The Journal of urology, 202(4), pp. 717–724. Available at: https://doi.org/10.1097/ju.0000000000000298.

Dugas SG et al. (2019) ‘Immunocytochemistry for ARID1A as a potential biomarker in urine cytology of bladder cancer’, Cancer Cytopathology, 127(9), pp. 578–585. Available at: https://doi.org/10.1002/cncy.22167.

Keller EX et al. (2019) ‘Prognostic value of unifocal and multifocal positive surgical margins in a large series of robot-assisted radical prostatectomy for prostate cancer.’, World journal of urology, 37(9), pp. 1837–1844. Available at: https://doi.org/10.1007/s00345-018-2578-y.

Burger IA et al. (2019) ‘(68)Ga-PSMA-11 PET/MR Detects Local Recurrence Occult on mpMRI in Prostate Cancer Patients After HIFU.’, Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 60(8), pp. 1118–1123. Available at: https://doi.org/10.2967/jnumed.118.221564.

Hench IB et al. (2019) ‘Analysis of AR/ARV7 expression in isolated circulating tumor cells of patients with metastatic castration-resistant prostate cancer (SAKK 08/14 IMPROVE trial)’, Cancers, 11(8). Available at: https://doi.org/10.3390/cancers11081099.

Kranzbühler B et al. (2019) ‘Combined N-terminal androgen receptor and autophagy inhibition increases the antitumor effect in enzalutamide sensitive and enzalutamide resistant prostate cancer cells.’, The Prostate, 79(2), pp. 206–214. Available at: https://doi.org/10.1002/pros.23725.

Lorber T et al. (2019) ‘Exploring the spatiotemporal genetic heterogeneity in metastatic lung adenocarcinoma using a nuclei flow-sorting approach’, Journal of Pathology, 247(2), pp. 199–213. Available at: https://doi.org/10.1002/path.5183.

Mortezavi A et al. (2019) ‘Inhibition of autophagy significantly increases the antitumor effect of Abiraterone in prostate cancer.’, World journal of urology, 37(2), pp. 351–358. Available at: https://doi.org/10.1007/s00345-018-2385-5.

Monteiro LL et al. (2019) ‘ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer’, World Journal of Urology, 37(1), pp. 51–60. Available at: https://doi.org/10.1007/s00345-018-2438-9.

Navone NM et al. (2018) ‘Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.’, The Prostate, 78(16), pp. 1262–1282. Available at: https://doi.org/10.1002/pros.23701.

Eberli D et al. (2018) ‘Increased autophagy contributes to impaired smooth muscle function in neurogenic lower urinary tract dysfunction.’, Neurourology and urodynamics, 37(8), pp. 2414–2424. Available at: https://doi.org/10.1002/nau.23705.

Juskevicius D et al. (2018) ‘Novel cell enrichment technique for robust genetic analysis of archival classical Hodgkin lymphoma tissues.’, Laboratory investigation; a journal of technical methods and pathology. 07.08.2018, 98(11), pp. 1487–1499. Available at: https://doi.org/10.1038/s41374-018-0096-6.

Omlin, Aurelius et al. (2018) ‘[Treatment of Advanced Prostate Carcinoma - an Interdisciplinary Recommendation].’, Praxis, 107(19), pp. 1043–1051. Available at: https://doi.org/10.1024/1661-8157/a003054.

Mortezavi A et al. (2018) ‘Diagnostic Accuracy of Multiparametric Magnetic Resonance Imaging and Fusion Guided Targeted Biopsy Evaluated by Transperineal Template Saturation Prostate Biopsy for the Detection and Characterization of Prostate Cancer.’, The Journal of urology, 200(2), pp. 309–318. Available at: https://doi.org/10.1016/j.juro.2018.02.067.

Pizzuto DA et al. (2018) ‘The central zone has increased (68)Ga-PSMA-11 uptake: ‘Mickey Mouse ears’ can be hot on (68)Ga-PSMA-11 PET.’, European journal of nuclear medicine and molecular imaging, 45(8), pp. 1335–1343. Available at: https://doi.org/10.1007/s00259-018-3979-2.

Rentsch CA et al. (2018) ‘Building on a Solid Foundation: Enhancing Bacillus Calmette-Guérin Therapy.’, European urology focus, 4(4), pp. 485–493. Available at: https://doi.org/10.1016/j.euf.2018.10.010.

Federer-Gsponer JR et al. (2018) ‘Delineation of human prostate cancer evolution identifies chromothripsis as a polyclonal event and FKBP4 as a potential driver of castration resistance.’, The Journal of pathology, 245(1), pp. 74–84. Available at: https://doi.org/10.1002/path.5052.

Müller DC et al. (2018) ‘Donor-derived, metastatic urothelial cancer after kidney transplantation associated with a potentially oncogenic BK polyomavirus.’, The Journal of pathology. 01.02.2018, 244(3), pp. 265–270. Available at: https://doi.org/10.1002/path.5012.

Leighton X et al. (2018) ‘Tissue microarray analysis delineate potential prognostic role of Annexin A7 in prostate cancer progression.’, PloS one, 13(10), p. e0205837. Available at: https://doi.org/10.1371/journal.pone.0205837.

Wetterauer, C et al. (2018) ‘Utility of cell based urinary tests in the follow-up after prostate cancer radiotherapy’, Annals of Urologic Research, 1(2).

Rentsch CA et al. (2017) ‘Comprehensive Molecular Characterization of Urothelial Bladder Carcinoma: A Step Closer to Clinical Translation?’, 72(6). Available at: https://doi.org/10.1016/j.eururo.2017.06.022.

Fröhlich M et al. (2017) ‘Extraction Strings for Ureteric Stents: Is There an Increased Risk for Urinary Tract Infections?’, Surgical infections, 18(8), pp. 936–940. Available at: https://doi.org/10.1089/sur.2017.165.

Becker AS et al. (2017) ‘Direct comparison of PI-RADS version 2 and version 1 regarding interreader agreement and diagnostic accuracy for the detection of clinically significant prostate cancer.’, European journal of radiology, 94, pp. 58–63. Available at: https://doi.org/10.1016/j.ejrad.2017.07.016.

Stenner, Frank et al. (2017) ‘Quality of Life in Second-Line Treatment of Metastatic Castration-Resistant Prostate Cancer Using Cabazitaxel or Other Therapies After Previous Docetaxel Chemotherapy: Swiss Observational Treatment Registry.’, Clinical genitourinary cancer [Preprint]. 24.08.2017. Available at: https://doi.org/10.1016/j.clgc.2017.08.003.

Chevalier MF et al. (2017) ‘ILC2-modulated T cell-to-MDSC balance is associated with bladder cancer recurrence.’, The Journal of clinical investigation. 26.06.2017, 127(8), pp. 2916–2929. Available at: https://doi.org/10.1172/jci89717.

Mason MD et al. (2017) ‘Adding Celecoxib With or Without Zoledronic Acid for Hormone-Naïve Prostate Cancer: Long-Term Survival Results From an Adaptive, Multiarm, Multistage, Platform, Randomized Controlled Trial.’, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 35(14), pp. 1530–1541. Available at: https://doi.org/10.1200/jco.2016.69.0677.

Mortezavi A et al. (2017) ‘Negative LC3b immunoreactivity in cancer cells is an independent prognostic predictor of prostate cancer specific death.’, Oncotarget, 8(19), pp. 31765–31774. Available at: https://doi.org/10.18632/oncotarget.15986.

Zhong Q et al. (2017) ‘A curated collection of tissue microarray images and clinical outcome data of prostate cancer patients.’, Scientific data, 4, p. 170014. Available at: https://doi.org/10.1038/sdata.2017.14.

Dasen B et al. (2017) ‘T-cadherin in prostate cancer: relationship with cancer progression, differentiation and drug resistance’, Journal of Pathology: Clinical Research, 3(1), pp. 44–57. Available at: https://doi.org/10.1002/cjp2.61.

Nieuwenhuizen NE et al. (2017) ‘The Recombinant Bacille Calmette-Guérin Vaccine VPM1002: Ready for Clinical Efficacy Testing.’, Frontiers in immunology, 8, p. 1147. Available at: https://doi.org/10.3389/fimmu.2017.01147.

Offermann A et al. (2017) ‘MED15 overexpression in prostate cancer arises during androgen deprivation therapy via PI3K/mTOR signaling’, Oncotarget, 8(5), pp. 7964–7976. Available at: https://doi.org/10.18632/oncotarget.13860.

Juskevicius D et al. (2016) ‘Distinct genetic evolution patterns of relapsing diffuse large B-cell lymphoma revealed by genome-wide copy number aberration and targeted sequencing analysis.’, Leukemia. 20.05.2016, 30(12), pp. 2385–2395. Available at: https://doi.org/10.1038/leu.2016.135.

Mortezavi A and Eberli D (2016) ‘Re: Prostate Cancer Detection with Magnetic Resonance-ultrasound Fusion Biopsy: The Role of Systematic and Targeted Biopsies.’, 70(5). Available at: https://doi.org/10.1016/j.eururo.2016.07.047.

Mortezavi A et al. (2016) ‘Clinical impact of prostate biopsy undergrading in an academic and community setting.’, World journal of urology, 34(10), pp. 1481–90. Available at: https://doi.org/10.1007/s00345-016-1788-4.

Mortezavi A et al. (2016) ‘Long-Term Oncologic Outcome of an Initial Series of Laparoscopic Radical Prostatectomy for Clinically Localized Prostate Cancer After a Median Follow-up of 10 Years.’, Clinical genitourinary cancer, 14(4), pp. 290–7. Available at: https://doi.org/10.1016/j.clgc.2015.11.006.

Rentsch C.A. et al. (2016) ‘Moving Towards Minimally Invasive Genomically Based Diagnosis and Monitoring of Bladder Cancer’, European Urology, 70(1), pp. 83–84. Available at: https://doi.org/10.1016/j.eururo.2016.02.050.

Randazzo, Marco et al. (2016) ‘A positive family history as a risk factor for prostate cancer in a population-based study with organised prostate-specific antigen screening: results of the Swiss European Randomised Study of Screening for Prostate Cancer (ERSPC, Aarau).’, BJU international, 117(4), pp. 576–83. Available at: https://doi.org/10.1111/bju.13310.

James, Nicholas D. et al. (2016) ‘Celecoxib with or without zoledronic acid for hormone-naive prostate cancer: Survival results from STAMPEDE (NCT00268476)’. AMER SOC CLINICAL ONCOLOGY, 34.

Ebbing J et al. (2016) ‘Dynamics of urinary calprotectin after renal ischaemia’, PLoS ONE, 11(1). Available at: https://doi.org/10.1371/journal.pone.0146395.

Andreozzi, Mariacarla et al. (2016) ‘HMGA1 Expression in Human Hepatocellular Carcinoma Correlates with Poor Prognosis and Promotes Tumor Growth and Migration in in vitro Models’, Neoplasia, 18(12), pp. 724–731. Available at: https://doi.org/10.1016/j.neo.2016.10.002.

Ruiz, C. et al. (2016) ‘Culture and Drug Profiling of Patient Derived Malignant Pleural Effusions for Personalized Cancer Medicine’, PLoS One, 11(8), p. e0160807. Available at: https://doi.org/10.1371/journal.pone.0160807.

Rentsch CA et al. (2015) ‘Three Genes to Predict Response to Chemotherapy for Bladder Cancer: Individualised Cancer Care at the Doorstep.’, 68(6). Available at: https://doi.org/10.1016/j.eururo.2015.07.050.

Mortezavi A, Schneider PM and Lurje G (2015) ‘An undigested cherry tomato as a rare cause of small bowel obstruction.’, Annals of the Royal College of Surgeons of England, 97(5), pp. e83–4. Available at: https://doi.org/10.1308/rcsann.2015.0004.

Wetterauer C et al. (2015) ‘Early development of human lymphomas in a prostate cancer xenograft program using triple knock-out Immunocompromised mice’, Prostate, 75(6), pp. 585–592. Available at: https://doi.org/10.1002/pros.22939.

Mauerhofer E et al. (2015) ‘Acute abdominal pain accompanied by high creatinine in a female patient with schizophrenia.’, Urology, 85(3), pp. 495–8. Available at: https://doi.org/10.1016/j.urology.2014.10.034.

Handschin, Christoph et al. (2015) ‘External physical and biochemical stimulation to enhance skeletal muscle bioengineering’, Advanced drug delivery reviews, pp. 168–75. Available at: https://doi.org/10.1016/j.addr.2014.10.021.

Keller, Xavier E. et al. (2015) ‘Antibody response to BK polyomavirus as a prognostic biomarker and potential therapeutic target in prostate cancer’, Oncotarget, 6(8), pp. 6459–69. Available at: https://doi.org/10.18632/oncotarget.3363.

Maslova, Kseniya et al. (2015) ‘EGFR and IGF-1R in regulation of prostate cancer cell phenotype and polarity: Opposing functions and modulation by T-cadherin’, FASEB Journal, 29, pp. 494–507. Available at: https://doi.org/10.1096/fj.14-249367.

Vedana M et al. (2015) ‘Primary synovial cell sarcoma of the kidney: case report and review of the literature.’, 8(1). Available at: https://doi.org/10.1159/000379740.